Evidence map›Paper›PMID 22240810›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2012

Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse.

Kristin A Anderson, Fumin Lin, Thomas J Ribar, Robert D Stevens, Michael J Muehlbauer, Christopher B Newgard, Anthony R Means

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular Mechanisms Underlying CaInternational journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kristin A AndersonDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Fumin Lin
Thomas J Ribar
Robert D Stevens
Michael J Muehlbauer
Christopher B Newgard
Anthony R Means
Duke University · USNational Institute of Environmental Health Sciences · US

Funding

TARGETED RESPONSIVE MR AND PET AGENTS FOR B-CELL IMAGINGP01DK058398 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MUOIO, DEBORAH M · 2000 to 2016
$26.1M
STRUCTURE/FUNCTION OF GENETIC ENGINEERED CALMODULINSR01GM033976 · NIGMS · DUKE UNIVERSITY · PI MEANS, ANTHONY R · 1985 to 2015
$5.4M
NIDDK NIH HHS P01 DK058398NIDDK NIH HHS P01DK58398NIGMS NIH HHS GM033976NIGMS NIH HHS R01 GM033976
6 · The paper itself

Abstract

Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a member of the Ca(2+)/CaM-dependent protein kinase family that is expressed abundantly in brain. Previous work has revealed that CaMKK2 knockout (CaMKK2 KO) mice eat less due to a central nervous system -signaling defect and are protected from diet-induced obesity, glucose intolerance, and insulin resistance. However, here we show that pair feeding of wild-type mice to match food consumption of CAMKK2 mice slows weight gain but fails to protect from diet-induced glucose intolerance, suggesting that other alterations in CaMKK2 KO mice are responsible for their improved glucose metabolism. CaMKK2 is shown to be expressed in liver and acute, specific reduction of the kinase in the liver of high-fat diet-fed CaMKK2(floxed) mice results in lowered blood glucose and improved glucose tolerance. Primary hepatocytes isolated from CaMKK2 KO mice produce less glucose and have decreased mRNA encoding peroxisome proliferator-activated receptor γ coactivator 1-α and the gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, and these mRNA fail to respond specifically to the stimulatory effect of catecholamine in a cell-autonomous manner. The mechanism responsible for suppressed gene induction in CaMKK2 KO hepatocytes may involve diminished phosphorylation of histone deacetylase 5, an event necessary in some contexts for derepression of the peroxisome proliferator-activated receptor γ coactivator 1-α promoter. Hepatocytes from CaMKK2 KO mice also show increased rates of de novo lipogenesis and fat oxidation. The changes in fat metabolism observed correlate with steatotic liver and altered acyl carnitine metabolomic profiles in CaMKK2 KO mice. Collectively, these results are consistent with suppressed catecholamine-induced induction of gluconeogenic gene expression in CaMKK2 KO mice that leads to improved whole-body glucose homeostasis despite the presence of increased hepatic fat content.

Indexed as

Blood GlucoseAdenylate KinaseAnimalsAntigens, NeoplasmCalcium-Calmodulin-Dependent Protein Kinase KinaseCarnitineCatecholaminesCells, CulturedDiet, High-FatEatingFatty LiverGene Knockout TechniquesGluconeogenesisGlucoseGlucose IntoleranceHepatocytesacylcarnitineAdenylate KinaseAntigens, NeoplasmBlood GlucoseCalcium-Calmodulin-Dependent Protein Kinase KinaseCamkk2 protein, mouseCarnitineCatecholaminesGlucoseLIPI protein, humanPhospholipases A1

Identifiers

PMID22240810
PMCPMC3275166
OpenAlexW2119750746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.